Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease.

David E Bernstein; Albert Tran; Paul Martin; Kris V Kowdley; Marc Bourliere; Mark S Sulkowski; Paul J Pockros; Boris Renjifo; Deli Wang; Diana L Shuster; Daniel E Cohen; Ira M Jacobson

doi:10.1016/j.ekir.2018.10.005

Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease.

David E Bernstein
, Albert Tran
, Paul Martin
, Kris V Kowdley
, Marc Bourliere
, Mark S Sulkowski
, Paul J Pockros
, Boris Renjifo
, Deli Wang
, Diana L Shuster
, Daniel E Cohen
, Ira M Jacobson

Research output: Contribution to journal › Article

7 Scopus citations

9 Downloads (Pure)

Abstract

Introduction: Patients with hepatitis C virus (HCV) infection and chronic kidney disease (CKD) are a high-priority population for treatment.

Methods: We performed a

Results: SVR12 rates in patients with stage 1, 2, and 3 CKD were 97% (439/453), 98% (536/547), and 97% (32/33), respectively, with OBV/PTV/r + DSV; and, 96% (1172/1221), 96% (1208/1254), and 93% (55/59), respectively, with OBV/PTV/r + DSV + RBV. Overall rates of serious AEs and renal AEs were 3% (95/3567) and 2% (56/3567), respectively. Factors associated with an eGFR increase of ≥10 ml/min per 1.73 m

Conclusion: OBV/PTV/r + DSV ± RBV achieved high SVR rates and was generally well tolerated irrespective of CKD stage.

Original language	American English
Pages (from-to)	245-256
Number of pages	12
Journal	Articles, Abstracts, and Reports
Volume	4
Issue number	2
DOIs	https://doi.org/10.1016/j.ekir.2018.10.005
State	Published - Feb 1 2019

Keywords

chronic hepatitis C
chronic kidney disease
direct-acting antiviral
hepatitis C virus

Access to Document

10.1016/j.ekir.2018.10.005License: Unspecified

Ombitasvir Paritaprevir Ritonavir and Dasabuvir With or Withou

http://digitalcommons.providence.org/publications/1137

Cite this

Bernstein, D. E., Tran, A., Martin, P., Kowdley, K. V., Bourliere, M., Sulkowski, M. S., Pockros, P. J., Renjifo, B., Wang, D., Shuster, D. L., Cohen, D. E., & Jacobson, I. M. (2019). Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease. Articles, Abstracts, and Reports, 4(2), 245-256. https://doi.org/10.1016/j.ekir.2018.10.005

@article{74ff09c4d8eb4f48a381fde7fcf39234,

title = "Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease.",

abstract = "Introduction: Patients with hepatitis C virus (HCV) infection and chronic kidney disease (CKD) are a high-priority population for treatment. Methods: We performed a Results: SVR12 rates in patients with stage 1, 2, and 3 CKD were 97\% (439/453), 98\% (536/547), and 97\% (32/33), respectively, with OBV/PTV/r + DSV; and, 96\% (1172/1221), 96\% (1208/1254), and 93\% (55/59), respectively, with OBV/PTV/r + DSV + RBV. Overall rates of serious AEs and renal AEs were 3\% (95/3567) and 2\% (56/3567), respectively. Factors associated with an eGFR increase of ≥10 ml/min per 1.73 m Conclusion: OBV/PTV/r + DSV ± RBV achieved high SVR rates and was generally well tolerated irrespective of CKD stage.",

keywords = "chronic hepatitis C, chronic kidney disease, direct-acting antiviral, hepatitis C virus",

author = "Bernstein, \{David E\} and Albert Tran and Paul Martin and Kowdley, \{Kris V\} and Marc Bourliere and Sulkowski, \{Mark S\} and Pockros, \{Paul J\} and Boris Renjifo and Deli Wang and Shuster, \{Diana L\} and Cohen, \{Daniel E\} and Jacobson, \{Ira M\}",

note = "Publisher Copyright: {\textcopyright} 2018 International Society of Nephrology",

year = "2019",

month = feb,

day = "1",

doi = "10.1016/j.ekir.2018.10.005",

language = "American English",

volume = "4",

pages = "245--256",

journal = "Articles, Abstracts, and Reports",

number = "2",

}

Bernstein, DE, Tran, A, Martin, P, Kowdley, KV, Bourliere, M, Sulkowski, MS, Pockros, PJ, Renjifo, B, Wang, D, Shuster, DL, Cohen, DE & Jacobson, IM 2019, 'Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease.', Articles, Abstracts, and Reports, vol. 4, no. 2, pp. 245-256. https://doi.org/10.1016/j.ekir.2018.10.005

TY - JOUR

T1 - Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease.

AU - Bernstein, David E

AU - Tran, Albert

AU - Martin, Paul

AU - Kowdley, Kris V

AU - Bourliere, Marc

AU - Sulkowski, Mark S

AU - Pockros, Paul J

AU - Renjifo, Boris

AU - Wang, Deli

AU - Shuster, Diana L

AU - Cohen, Daniel E

AU - Jacobson, Ira M

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Introduction: Patients with hepatitis C virus (HCV) infection and chronic kidney disease (CKD) are a high-priority population for treatment. Methods: We performed a Results: SVR12 rates in patients with stage 1, 2, and 3 CKD were 97% (439/453), 98% (536/547), and 97% (32/33), respectively, with OBV/PTV/r + DSV; and, 96% (1172/1221), 96% (1208/1254), and 93% (55/59), respectively, with OBV/PTV/r + DSV + RBV. Overall rates of serious AEs and renal AEs were 3% (95/3567) and 2% (56/3567), respectively. Factors associated with an eGFR increase of ≥10 ml/min per 1.73 m Conclusion: OBV/PTV/r + DSV ± RBV achieved high SVR rates and was generally well tolerated irrespective of CKD stage.

AB - Introduction: Patients with hepatitis C virus (HCV) infection and chronic kidney disease (CKD) are a high-priority population for treatment. Methods: We performed a Results: SVR12 rates in patients with stage 1, 2, and 3 CKD were 97% (439/453), 98% (536/547), and 97% (32/33), respectively, with OBV/PTV/r + DSV; and, 96% (1172/1221), 96% (1208/1254), and 93% (55/59), respectively, with OBV/PTV/r + DSV + RBV. Overall rates of serious AEs and renal AEs were 3% (95/3567) and 2% (56/3567), respectively. Factors associated with an eGFR increase of ≥10 ml/min per 1.73 m Conclusion: OBV/PTV/r + DSV ± RBV achieved high SVR rates and was generally well tolerated irrespective of CKD stage.

KW - chronic hepatitis C

KW - chronic kidney disease

KW - direct-acting antiviral

KW - hepatitis C virus

UR - https://www.scopus.com/pages/publications/85057369772

U2 - 10.1016/j.ekir.2018.10.005

DO - 10.1016/j.ekir.2018.10.005

M3 - Article

VL - 4

SP - 245

EP - 256

JO - Articles, Abstracts, and Reports

JF - Articles, Abstracts, and Reports

IS - 2

ER -

Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease.

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this